Drugs Made In America Acquisition Corp. (DMAAU) Total Liabilities (2024 - 2025)
Drugs Made In America Acquisition's (DMAAU) quarterly Total Liabilities came in at $7.3 million in Q4 2025, up 814.47% YoY from $795669.0 in Q4 2024, and down 1.09% on a QoQ basis from $7.4 million in Q3 2025.
Drugs Made In America Acquisition Corp. (DMAAU) Total Liabilities (2024 - 2025) Analysis & Trends
Drugs Made In America Acquisition (DMAAU) has 2 years of Total Liabilities data on file, last reported at $7.3 million in Q4 2025.
- Quarterly Total Liabilities rose 814.47% year-over-year to $7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.3 million (up 814.47% YoY) and the FY2025 annual result came in at $7.3 million, up 814.47% from the prior year.
- Total Liabilities fell to $7.3 million in Q4 2025, from $7.4 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $7.4 million in Q3 2025 to a low of $795669.0 in Q4 2024.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.28 Mn |
| Sep 30, 2025 | 7.36 Mn |
| Jun 30, 2025 | 7.20 Mn |
| Mar 31, 2025 | 7.25 Mn |
| Dec 31, 2024 | 795,669.00 |